Oxford Textbook of Rheumatoid Arthritis

David L. Scott is Professor of Clinical Rheumatology at King's College London. He trained in medicine and rheumatology in Leeds and Birmingham and subsequently held a fellowship at St Bartholomew's Hospital in London. His current academic focus spans the outcomes of rheumatoid arthritis and the impact of intensive treatment in improving outcomes in clinical trials. James Galloway is Senior Lecturer in Rheumatology at King's College London and Honorary Consultant Rheumatologist at King's College Hospital. After training in medicine and rheumatology in Bristol and Manchester he held a fellowship at the Arthritis Research UK Epidemiology Unit in Manchester. His current academic focus is on large observational studies of arthritis and treatment risks including infections Andrew Cope is Arthritis Research UK Professor of Rheumatology at King's College London and Honorary Consultant Rheumatologist at Guy's and St Thomas's Hospital. After training in medicine and rheumatology in London he held fellowships at the Kennedy Institute of Rheumatology and Stanford University. His current academic focus spans laboratory studies, clinical trials and observational studies with an emphasis on understanding the immunobiology of inflammatory arthritis. Arthur Pratt is Clinical Fellow in the Institute of Cellular Medicine and Honorary Consultant Rheumatologist at the Freeman Hospital in Newcastle. He trained in medicine and rheumatology in Leeds and Newcastle. Subsequently he was a training fellow and National Institute for Health Clinical Lecturer at Newcastle University. His current academic focus is clinical and laboratory assessments and predictors in early inflammatory arthritis. Vibeke Strand is Adjunct Clinical Professor, in the Division of Immunology and Rheumatology at Stanford University. She is a clinical rheumatologist and acts as a consultant in biopharmaceutics, clinical research, and regulatory affairs to many pharmaceutical and biotech companies. After graduating from Swarthmore College she trained in medicine and rheumatology at University of California San Francisco School of Medicine. Her current academic focus spans clinical trial design, development of outcome measures with an emphasis on patient reported outcomes and regulatory strategies leading to approval of new agents for treatment of autoimmune diseases. She gives particular emphasis to translating basic research findings into rationally designed clinical trials, evaluating their results and helping patients access new treatments.

1. History, diagnosis, and epidemiology
1: David L. Scott: The history of rheumatoid arthritis
2: Daniel Aletaha and Helga Radner: Diagnosis
3: James Gwinnutt and Deborah Symmons: The descriptive epidemiology of rheumatoid arthritis
4: Lars Klareskog and Lars Alfredsson: Modifiable and other risk factors for rheumatoid arthritis: a basis for prevention and better therapy
2. Pathogenesis
5: Anne Barton: Genetics and epigenetics of rheumatoid arthritis
6: Thomas Crowley, Jason Turner, Andrew Filer, Andy Clark, and Chris Buckley: Dysregulation of synovial fibroblasts in rheumatoid arthritis
7: Tom W. J. Huizinga: Autoantibodies in rheumatoid arthritis
8: Soi-Cheng Law, Pascale Wehr, Harriet Purvis, and Ranjeny Thomas: Dendritic cells and T cells in rheumatoid arthritis
9: Ukrike Steffen and Georg Schett: Mechanisms of bone and cartilage destruction
10: Marina Frleta-Gilchrist and Iain B. McInnes: Cytokines and other mediators
3. Clinical presentation
11: Annette van der Helm-van Mil: Clinical features of rheumatoid arthritis
12: Karim Raza, Catherine McGrath, Laurette van Boheemen, and Dirkjan van Schaardenburg: Pre-rheumatoid arthritis
13: Katherine MacDonald, Jennifer Hannah, and James Galloway: Non-articular manifestations of rheumatoid arthritis
14: Kimme Hyrich and Sarah Skeoch: Comorbidity in rheumatoid arthritis
4. Disease assessment
15: Josef Smolen: Disease activity assessment in rheumatoid arthritis
16: Douglas Veale and Ursula Fearon: Synovial biopsies
17: Charles Peterfy, Philip Conaghan, and Mikkel Østergaard: Radiography in rheumatoid arthritis
18: Andrew Filer, Maria Antonietta D'Agostino, and Ilfita Sahbudin: Ultrasound in rheumatoid arthritis
19: Charles Peterfy, Philip Conaghan, and Mikkel Østergaard: MRI in rheumatoid arthritis
5. Impact on life
20: Kathryn A. Gibson and Theodore Pincus: Patient physical function in rheumatoid arthritis
21: Emma Dures and Neil Basu: Fatigue
22: David L. Scott and Allan Wailoo: Health economics
23: Suzanne Verstappen, Cheryl Jones, Abdullah Houssien, and James Galloway: Rheumatoid arthritis and work
6. Non-drug treatments
24: Lindsay Bearne and Christina Opava: Exercise
25: Heidi Siddle and Anthony Redmond: Foot health
26: Alison Hammond, Joanne Adams, and Yeliz Prior: Occupational therapy
27: Marieke M.J.H. Voshaar: Self-management: a patient's perspective
7. Drug treatments
28: Mark D Russell and Nidhi Sofat: Analgesics, Opioids, and NSAIDs
29: Johannes W. G. Jacobs, Marlies C. van der Goes, Johannes W. J. Bijlsma, and José A. P. da Silva: Glucocorticoids
30: David L. Scott: Conventional disease modifying drugs
31: Peter Taylor and Nehal Narayan: Tumour necrosis factor inhibitors
32: Neelam Hassan and Ernest Choy: Interleukin-6 inhibitors
33: Yuzaiful Yusof, Edward Vital, and Maya Buch: B-cell therapies
34: Vibeke Strand, Jeffrey Kaine, and John Isaacs: Biosimilars
35: Meghna Jani, John Isaacs, and Vibeke Strand: Immunogenicity in response to biologic agents
36: Katie Bechman, James Galloway, and Peter Taylor: The use of JAK inhibitors in the treatment of rheumatoid arthritis
37: Ben G.T. Coumbe, Elena Nikiphorou, and Tuulikki Sokka-Isler: Combination therapy in rheumatoid arthritis
38: Jeremy Sokolove: Translation of new therapies: from bench to bedside
39: James Galloway and Mark Yates: Adverse events in clinical studies in rheumatoid arthritis
8. Management and outcomes
40: Tom W. J. Huizinga, Annette van der Helm-van Mil, and Andrew Cope: Prevention of rheumatoid arthritis
41: Kenneth F Baker and Arthur G Pratt: Treatment targets and remission
42: David L. Scott: Clinical outcomes
43: Anna-Birgitte Aga, Espen A. Haavardsholm, Till Uhlig, and Tore K. Kvien: Clinical guidelines
44: Angela Zink and Anja Strangfeld: European biologics registers
45: Jeff Greenberg and Sheetal Patel: Voluntary patient registries